Holen Sie sich die Stockscreener-App
77.94
5.05%
-4.565
Schlusskurs vom Vortag:
$82.51
Offen:
$82.51
24-Stunden-Volumen:
133.64K
Relative Volume:
0.16
Marktkapitalisierung:
$4.27B
Einnahmen:
$1.34M
Nettoeinkommen (Verlust:
$-173.66M
KGV:
-18.83
EPS:
-4.1385
Netto-Cashflow:
$-130.49M
1W Leistung:
-7.37%
1M Leistung:
-9.08%
6M Leistung:
+89.23%
1J Leistung:
+329.97%
1-Tages-Spanne:
$77.61
$82.61
1-Wochen-Bereich:
$68.85
$84.75
52-Wochen-Spanne:
$16.64
$96.50
Dianthus Therapeutics Inc Stock (DNTH) Company Profile
Firmenname
Dianthus Therapeutics Inc
Sektor
Branche
Telefon
929-999-4055
Adresse
7 TIMES SQUARE, NEW YORK
Compare DNTH vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DNTH
Dianthus Therapeutics Inc
|
78.08 | 4.51B | 1.34M | -173.66M | -130.49M | -4.1385 |
VRTX
Vertex Pharmaceuticals Inc
|
449.25 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
611.21 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
879.53 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
279.13 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
155.32 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-09 | Eingeleitet | Wolfe Research | Outperform |
| 2026-03-10 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2025-10-14 | Eingeleitet | Truist | Buy |
| 2025-07-02 | Eingeleitet | William Blair | Outperform |
| 2024-12-20 | Eingeleitet | TD Cowen | Buy |
| 2024-10-03 | Eingeleitet | Oppenheimer | Outperform |
| 2024-07-26 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-06-27 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-05-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-02-15 | Eingeleitet | Stifel | Buy |
| 2023-12-26 | Eingeleitet | Jefferies | Buy |
| 2023-11-22 | Eingeleitet | Wedbush | Outperform |
| 2023-10-30 | Eingeleitet | Guggenheim | Buy |
| 2023-09-28 | Eingeleitet | Raymond James | Outperform |
| 2022-08-25 | Herabstufung | Goldman | Buy → Neutral |
| 2022-01-06 | Hochstufung | Goldman | Neutral → Buy |
| 2021-08-20 | Fortgesetzt | Goldman | Neutral |
| 2021-08-03 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-07-22 | Bestätigt | B. Riley Securities | Buy |
| 2021-06-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-05-18 | Eingeleitet | B. Riley Securities | Buy |
| 2021-01-07 | Eingeleitet | Mizuho | Buy |
| 2020-06-08 | Hochstufung | Goldman | Neutral → Buy |
| 2019-03-25 | Herabstufung | Goldman | Buy → Neutral |
| 2019-03-15 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Dianthus Therapeutics Inc Aktie (DNTH) Neueste Nachrichten
DNTH stock clocks best day in over 3 months on strong nerve disorder study results - MSN
Dianthus drops as Sanofi halts late-stage trial for CIDP therapy on efficacy concerns - MSN
DNTH Stock Clocks Best Day In Over 3 Months On Strong Nerve Disorder Study Results - TradingView
Why Is Dianthus Therapeutics Stock Trading Higher On Friday? - Benzinga
Dianthus Therapeutics posts interim CAPTIVATE responder data; 75% response in first 40 CIDP patients - TradingView
Dianthus Therapeutics (DNTH) details interim Phase 3 CIDP results, Phase 2 gMG data and $1.2B runway - Stock Titan
Dianthus Therapeutics: Sanofi's CIPD Study Fail Poses Uncomfortable Questions - Seeking Alpha
Sanofi Trial Setback May Reinforce Argenx Vyvgart's Position In CIDP, Analyst Says - Benzinga
Sanofi Trial Setback May Reinforce Argenx Vyvgart's Position In CIDP, Analyst Says - Sahm
Guggenheim reiterates Dianthus stock rating citing potency edge By Investing.com - Investing.com Nigeria
Dianthus Therapeutics Down Over 9%, On Track for Largest Percent Decrease Since January 2025 -- Data Talk - Moomoo
Dianthus Therapeutics stock rating maintained at Buy by TD Cowen - Investing.com Canada
Dianthus Therapeutics stock falls on Sanofi CIDP trial halt By Investing.com - Investing.com South Africa
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch? - BioWorld News
Truist reiterates Dianthus Therapeutics stock rating after rival trial halt By Investing.com - Investing.com Canada
Sanofi (SNY) Halts Phase 3 Study, Impacting Dianthus Therapeutics - GuruFocus
Why is Dianthus Therapeutics stock plunging today? By Investing.com - Investing.com Canada
Stifel reiterates Dianthus Therapeutics stock Buy on rival setback By Investing.com - Investing.com Canada
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Will Orphan Drug Status And Advancing Autoimmune Pipeline Change Dianthus Therapeutics' (DNTH) Narrative - Yahoo Finance
DNTH: Advancing potent neuromuscular and rheumatology assets with robust funding and rapid execution - TradingView
DNTH Stock Soars After Early ‘Go’ Decision For Drug In Autoimmune Disorder Program, Boosting Wall Street Optimism For Potential Launch - Stocktwits
Gross profit of Dianthus Therapeutics, Inc. – XETR:87E - TradingView
Net debt of Dianthus Therapeutics, Inc. – XETR:87E - TradingView
Enterprise value of Dianthus Therapeutics, Inc. – XETR:87E - TradingView
Net income before discontinued operations of Dianthus Therapeutics, Inc. – XETR:87E - TradingView
Return on equity % of Dianthus Therapeutics, Inc. – XETR:87E - TradingView
Dianthus Therapeutics, Inc. Balance Sheet – XETR:87E - TradingView
Dianthus Therapeutics, Inc. Statistics – XETR:87E - TradingView
BNP Paribas Financial Markets Boosts Stake in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Assessing Dianthus Therapeutics (DNTH) Valuation After FDA Eases Claseprubart Trial Screening Rules - Sahm
Dianthus Therapeutics (DNTH) Appears Attractive Amid Solid Product Pipeline - Insider Monkey
DNTH: Multiple pivotal trials advance with key data and strong cash runway supporting growth - TradingView
Dianthus Therapeutics Inc (DNTH): FDA Makes Trials Easier - Yahoo Finance
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Dianthus Therapeutics EVP Randhawa sells $2.4m in company stock By Investing.com - Investing.com South Africa
Dianthus Therapeutics EVP Randhawa sells $2.4m in company stock - Investing.com
Dianthus Therapeutics (DNTH) EVP sells 26,530 shares after option exercises - Stock Titan
DNTH (NASDAQ) director files Form 144 to sell 26,530 shares - Stock Titan
Top Avalyn Pharma (AVLN) Competitors 2026 - MarketBeat
Dianthus Therapeutics: A Financed Autoimmune Platform With More Than One Way To Win (NASDAQ:DNTH) - Seeking Alpha
Dianthus Therapeutics (DNTH) Surges 4.37% as Stock Nears Key Resistance LevelDemand Zone - The Legal Advocate
DNTH Stock Price, Quote & Chart | DIANTHUS THERAPEUTICS INC (NASDAQ:DNTH) - ChartMill
Biotech Dianthus to meet investors at Jefferies and Goldman events - Stock Titan
Dianthus Therapeutics to Participate in Two Investor Conferences - Yahoo Finance
Dianthus Therapeutics (DNTH) Declines Amid Sector Pressure, Support Levels in FocusRevenue Weighted - The Legal Advocate
Dianthus Therapeutics Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost DisciplineDownward Estimate Revision - newsline.com
Dianthus Therapeutics Q1 2026 Earnings: Better-than-Expected Loss Despite No RevenuePost-Earnings Drift - The Legal Advocate
Dianthus (DNTH) director receives 6,090 options vesting by 2027 - Stock Titan
Dianthus Therapeutics (DNTH) awards director 6,090 stock options at $89.63 - Stock Titan
Director at Dianthus Therapeutics (DNTH) granted 6,090 stock options - Stock Titan
Finanzdaten der Dianthus Therapeutics Inc-Aktie (DNTH)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.61%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):